Rheumatology key messagesExogenous SPARC induces a pro-fibrotic phenotype in dermal fibroblast from systemic sclerosis patients.The pro-fibrotic of SPARC is mediated by the activation of the TGF-β signalling in systemic sclerosis patients.

Introduction
============

SSc is an autoimmune disease characterized by inflammation, vascular injury and fibrosis in different organs that carries a high burden of morbidity and mortality. SSc is recognized as one of the most severe connective tissue disorders, associated with the highest case-specific mortality among all the rheumatic diseases, and for which hardly any therapeutic options are available \[[@kez583-B1]\]. Fibrosis is the main feature of SSc pathology and is characterized by the excessive production of extracellular matrix (ECM) proteins, including collagen (Col) family members, vimentin and fibronectin, as well as by the differentiation of different cell types (mainly fibroblasts but also endothelial cells and pericytes) into myofibroblasts, which are defined by the expression of the contractile protein α smooth muscle actin \[[@kez583-B2]\].

SPARC (secreted protein acidic and rich in cysteine, also known as osteonectin and BM-40) is a member of a larger family of SPARC-related matricellular glycoproteins, which are ECM associated proteins, but in contrast to the classical ECM proteins (Col, laminin, fibronectin), do not have a structural role. SPARC binds to ECM components, such as fibrillar Col I, II and III and basal lamina Col IV, as well as cellular receptors and secreted growth factors, leading to the regulation of different processes involved in homeostasis and disease, including cell migration and invasion, tissue remodelling, cell proliferation, wound healing, angiogenesis, immune responses and fibrosis. SPARC is associated with several different pathologies, including obesity, diabetes, cataracts, myocardial infarct and fibrotic diseases \[[@kez583-B3], [@kez583-B4]\]. *In vivo* experiments have highlighted a key role for this protein in SSc pathology, as SPARC-deficient mice, as well as adenoviral or siRNA-mediated silencing of SPARC expression, reduces disease severity in the bleomycin-induced skin and lung fibrosis model \[[@kez583-B5], [@kez583-B6]\]. Importantly, SPARC expression is elevated in serum and affected skin of SSc patients \[[@kez583-B7], [@kez583-B8]\], as well in dermal fibroblasts, and SPARC silencing reduced the production of Col I, Col III and connective tissue growth factor (CTGF) by these cells \[[@kez583-B9], [@kez583-B10]\]. While these studies implicate SPARC in the fibrotic events observed in SSc pathology, it is unclear if these effects are mediated by intracellular SPARC, or extracellular SPARC which latter could be targeted by antibodies. Increasing the knowledge on SPARC biology and roles thus has relevance for therapeutic targeting of fibrosis.

Methods
=======

Patients
--------

Skin from patients and sex- and age-matched healthy controls (HC) was obtained from the University Medical Centre Utrecht (The Netherlands). All patients provided informed written consent approved by the local institutional medical ethics review boards prior to inclusion in this study. Samples and clinical information were treated anonymously immediately after collection. Patients fulfilled the ACR/EULAR 2013 classification criteria for SSc \[[@kez583-B11]\], and the demographic and clinical characteristics of the patients are detailed in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online.

Dermal fibroblast culture and stimulation
-----------------------------------------

SSc dermal fibroblasts were isolated from 3 to 4 mm skin biopsies obtained from a clinically affected area. HC dermal fibroblasts were obtained from skin biopsies taken from resected material after cosmetic surgery. Dermal fibroblast isolation was performed using a whole skin dissociation kit (Miltenyi Biotec, Leiden, The Netherlands) following the manufacturer's instructions and fibroblasts were routinely maintained in Fibroblast Basal Medium supplemented with Fibroblasts Growth Kit-Low Serum (both from ATCC, Manassas, Virginia, USA). Cells were used for experiments between passages 3 and 5 and stimulations were performed after overnight culture. Fibroblasts were left unstimulated or were stimulated with different concentrations of SPARC (0.1--10 μg/ml, R&D Systems, Abingdon, United Kingdom) alone or in combination with TGF-β1 (10 ng/ml, Biolegend, London, United Kingdom) for 1, 6, 24 or 48 h. Alternatively, fibroblasts were pre-incubated for 1 h at 37°C in the presence of the TGFR1 inhibitor Galunisertib (10 nM, Selleck, Munich, Germany) and further stimulated with SPARC (1 μg/ml) alone or in in combination with TGF-β1 (10 ng/ml) for 24 and 48 h.

RT-PCR and quantitative (q)PCR
------------------------------

RNA from dermal fibroblasts was isolated using the RNeasy micro Kit and RNase-Free DNase Set (Qiagen, Venlo, The Netherlands). Total RNA was reverse-transcribed using an iScript cDNA Synthesis kit (Biorad, Veenendaal, The Netherlands). Duplicate PCR reactions were performed using SYBR green (Applied Biosystems, Bleiswijk, The Netherlands) with a StepOne Plus Real-Time PCR system (Applied Biosystems). cDNA was amplified using specific primers (all from Integrated DNA Technologies, Inc. (IDT), see [Supplementary Table S2](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online, for primer sequences). Relative levels of gene expression were normalized to *B2M* housekeeping gene. The relative quantity of mRNA was calculated using 2^−ΔΔCt^.

Immunoblotting
--------------

Dermal fibroblasts were lysed in Laemmli's buffer and protein content was quantified with a BCA Protein Assay Kit (Thermo Fisher Scientific, Bleiswijk, The Netherlands). Equivalent amounts of total protein lysate were subjected to electrophoresis on NuPAG 4--12% Bis-Tris Protein Gels (Thermo Fisher Scientific) and proteins were transferred to polyvinylidene difluoride membranes (Millipore). Membranes were incubated overnight at 4°C with primary antibodies specific for SPARC, histone 3 (H3), SMAD family member 2 (SMAD2) (all from Cell Signalling, Leiden, The Netherlands), Col I (Millipore, Amsterdam, The Netherlands), Col IV, TGF-β (both from Abcam, Oxford, UK), fibronectin (Bio-Techne, Abingdon, UK) and p(hospho)-SMAD2 (Thermo Fisher Scientific). Membranes were then washed and incubated in tris-buffered saline / Tween 20 containing horseradish peroxidase--conjugated secondary antibody. Protein was detected with Lumi-lightplus Western Blotting Substrate (Roche Diagnostics, Almere, The Netherlands) using a ChemiDoc™ MP System (Biorad). Densitometry analysis was performed with Image J software. Relative protein expression and relative SMAD2 activation was normalized to H3 and SMAD2 expression, respectively.

Statistical analysis
--------------------

Statistical analysis was performed using GraphPad Prism 7 software (GraphPad Software Inc., San Diego, CA, US). Potential differences between experimental groups were analysed by a non-parametric, Kruskal--Wallis test or Friedman test, as appropriate. *P* \< 0.05 was considered statistically significant.

Results
=======

Exogenous SPARC induces the expression of ECM components and fibrotic mediators by SSc patient dermal fibroblasts
-----------------------------------------------------------------------------------------------------------------

SPARC silencing reduces the expression of fibrotic mediators by dermal fibroblasts of SSc patients \[[@kez583-B10]\], but the effect of exogenous administration of SPARC is unknown. We first determined the effect of exogenous SPARC administration on the mRNA expression of ECM or fibrotic genes in dermal fibroblasts from HC and SSc patients. As the phenotypic characteristics of fibroblasts are dependent of the location \[[@kez583-B12]\], we analysed the effect of SPARC in fibroblast obtained from forearm, breast and abdominal tissue of HC. We observed that SPARC does not regulate the mRNA expression of ECM or fibrotic genes in HC fibroblast, independently of the tissue location ([Fig. 1A](#kez583-F1){ref-type="fig"}). In contrast, exogenous SPARC significantly up-regulated the mRNA expression of the ECM components *COL1A1, COL4A1, COL4A2* and *fibronectin-1 (FN1)*, and the fibrosis-related genes *TGF-β1, PAI-1, PDGF-A* and *SPARC* itself by SSc patient dermal fibroblasts. We also observed a trend towards up-regulation of *CTGF* and *ACTA2* ([Fig. 1B](#kez583-F1){ref-type="fig"}). We further validated these findings at the protein level as we found that exogenous SPARC induced the expression of Col I, Col IV, FN1 and TGF-β1 in fibroblasts from SSc patients, but not from HC ([Fig. 1C and D](#kez583-F1){ref-type="fig"}). To determine whether the effect of exogenous SPARC was dose-dependent, we stimulated fibroblasts from HC and SSc patients with different concentrations of SPARC. In fibroblasts from HC, SPARC did not induce expression of fibrosis-related genes in any of the concentrations used. In dermal fibroblasts of SSc patients, exogenous SPARC induced the expression of *COL1A1, COL4A1, COL4A2, FN1* and *SPARC* in a dose-dependent manner in the range of 0.01--1 µg/ml ([Supplementary Fig. S1](#sup1){ref-type="supplementary-material"}, available at *Rheumatology* online). These results provide the first direct evidence that exogenous SPARC can regulate pro-fibrotic gene expression in SSc fibroblasts.

![SPARC induces the expression of ECM components and fibrotic mediators in dermal fibroblast of SSc patients\
(**A** and **B**) mRNA expression of ECM components and fibrotic genes by dermal fibroblast from breast (open squares), abdomen (filled squares) or forearm (open circles) of HC (**A**) and from forearm of lcSSc (open circles) and dcSSc patients (filled squares) (**B**) stimulated with SPARC (1 µg/ml) for 24 h. (**C** and **D**) Representative immunoblots (**C**) and densitometric analysis (**D**) of Col I, Col IV, fibronectin, TGF-β and SPARC protein expression in dermal fibroblasts of HC and SSc patients stimulated with SPARC (1 µg/ml) for 48 h. Data is shown as relative expression with respect to H3 expression. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 compared with medium. HC: healthy controls; SPARC: secreted protein acidic and rich in cysteine; ECM: extracellular matrix.](kez583f1){#kez583-F1}

Pro-fibrotic effect of SPARC is mediated by TGF-β1 signalling
-------------------------------------------------------------

We next investigated the mechanisms that could explain the differences in the effect of exogenous SPARC between HC and SSc patient dermal fibroblasts. As previous studies have shown that SPARC may interact with TGF-β1 signalling pathways \[[@kez583-B13], [@kez583-B14]\] we analysed the phosphorylation status of SMAD2, a tyrosine kinase substrate in the TGF-β1 signalling pathway \[[@kez583-B15]\], in dermal fibroblasts from HC and SSc patients. Non-stimulated fibroblasts from SSc patients displayed a higher phosphorylation of SMAD2 compared with HC fibroblasts ([Fig. 2A](#kez583-F2){ref-type="fig"}). Importantly, exogenous SPARC induced SMAD2 activation in SSc patient fibroblasts, but had no effect in fibroblasts from HC. As these results suggested SPARC may interact with autocrine TGF-β1 signalling in SSc fibroblasts, we examined the effects of SPARC on SSc fibroblasts in the absence or presence of a TGFB-R1 antagonist (Galunisertib -LY2157299-). Strikingly, the effect of SPARC was almost fully abrogated by blocking TGF-β signalling ([Fig. 2B](#kez583-F2){ref-type="fig"}).

![SPARC induces the expression of ECM components and fibrotic mediators in a TGF-β signalling dependent manner\
(**A**) Representative immunoblots of SMAD2 activation in dermal fibroblasts of HC and SSc patients stimulated with SPARC (1 µg/ml) for 1 and 6 h. (**B**) Representative immunoblots of Col I, fibronectin and TGF-β protein expression in skin fibroblasts of SSc patients pre-incubated 1 h with a TGB-R1 inhibitor (10 nM) and further stimulated with SPARC (1 µg/ml) for 48 h. (**C**) mRNA expression of ECM components by skin fibroblast of HC stimulated with SPARC (1 µg/ml) alone or in combination with TGF-β1 (10 ng/ml) for 24 h. Data is shown as connected dots. (**D**) Representative immunoblots of Col I and fibronectin protein expression in skin fibroblasts of HC stimulated with SPARC (1 µg/ml) alone or in combination with TGF-β1 (10 ng/ml) for 48 h. \#*P* \< 0.05 and \#\# *P* \< 0.01 compared with medium. \**P* \< 0.05 and \*\**P* \< 0.01. HC: healthy controls; SPARC: secreted protein acidic and rich in cysteine; ECM: extracellular matrix.](kez583f2){#kez583-F2}

Reciprocally, while exogenous SPARC alone did not modulate the expression of ECM components or fibrosis-related genes in HC dermal fibroblasts, exogenous SPARC significantly enhanced the TGF-β1 induced expression of *COL1A1*, *COL1A2*, *COL4A1*, *COL4A2*, *FN1* and *PAI-1* ([Fig. 2C](#kez583-F2){ref-type="fig"}). Changes observed in mRNA expression were relevant to fibroblast protein production, as we found that SPARC enhanced the TGF-β1 induced secretion of Col I and fibronectin by HC fibroblasts ([Fig. 2D](#kez583-F2){ref-type="fig"}). Together, these results demonstrate that extracellular SPARC induces a pro-fibrotic phenotype of fibroblasts from SSc patients by sensitizing them for TGF-β1 mediated activation.

Discussion
==========

SPARC levels are elevated in the serum, affected skin and isolated skin fibroblasts from SSc patients. Next, lowering SPARC levels resulted in reduced fibrosis in mice models of SSc and the expression of ECM components by dermal fibroblasts of SSc patients \[[@kez583-B5], [@kez583-B6], [@kez583-B10]\]. These studies implicate an important role of SPARC in fibrosis and justify further research as understanding the mode of action of SPARC could provide important insight for SPARC as a therapeutic target. In the present study we provide evidence that exogenous SPARC is able to induce a pro-fibrotic phenotype in dermal fibroblasts of SSc patients. This effect was not observed in HC fibroblasts, likely due to the absence of constitutive activation of TGF-β signalling pathways. TGF-β is one of the most important fibrotic mediators involved in SSc pathology and several studies have shown that TGF-β expression is elevated in the serum and skin of SSc patients, and induces the production of ECM components and other fibrotic mediators such as CTGF, thromboposdin-1 and Serpine1, the protein encoded by the gene *PAI-1* \[[@kez583-B15]\]. Importantly, TGF-β induces the expression of SPARC by dermal fibroblasts \[[@kez583-B13], [@kez583-B16]\] and reciprocally, SPARC induces the expression of TGF-β and regulates TGF-β induced apoptosis and fibrosis \[[@kez583-B13], [@kez583-B14]\], suggesting a functional link between these two proteins. In this study, we found that SPARC induces the expression of TGF-β and the activation SMAD2, a key transcription factor downstream of TGF-β signalling, in SSc dermal fibroblasts. Moreover, the inhibition of autocrine TGF-β1 signalling abrogated SPARC-induced gene expression, demonstrating a feedback loop between SPARC and TGF-β1 that contributes to the fibrotic phenotype observed in SSc pathology. Consistent with this, exogenous SPARC enhances TGF-β induced expression of ECM components and fibrotic mediators by HC dermal fibroblasts, resembling the phenotype of SPARC-stimulated SSc fibroblasts. This finding supports the cooperative role of SPARC in fibrotic processes induced by TGF-β signalling. In homeostatic conditions, exogenous SPARC does not induce a pro-fibrotic phenotype in dermal fibroblast. However, in a TGF-β-induced pro-fibrotic environment, exogenous SPARC enhances the fibrotic phenotype of dermal fibroblasts. Therefore, SPARC neutralization could be an interesting approach for reducing fibrosis even in advanced stages of SSc.
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